MKI The Medipattern Corp.

The Medipattern Corporation ("Medipattern") (TSX VENTURE: MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, is pleased to announce the on-time release of Visualize:Vascular™ 1.1. Shipments have started and the first sites have been installed.

"Visualize:Vascular's 3D rendering for carotid arteries really is an eye opening experience. This is the first time that I can clearly see the anatomy of the lumen from any perspective using ultrasound imaging," commented Farouq Samhouri, M.D., President of Northeast Philadelphia Vascular Surgery (NEPVS) in Pennsylvania. "Ultrasound is a key imaging test for us. Ultrasound is cost effective and convenient. We perform the exam right in our offices. There is no need for the patient to have to go to the hospital. We have immediate access using this real-time imaging technique every time our patients come in for a visit and now we see the whole lumen in 3D. There were often lingering questions when we relied solely on 2D imaging; questions as to whether something could be missing, hidden, or lurking in the shadows."

Dr. Samhouri continues, "The only way to see the lumen in 3D prior to Visualize:Vascular was to order a procedure which had to be done in the hospital, such as Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA). While I use CTA and MRA as pre-surgical tests and would still use these as pre-surgical tests, they expose the patient to radiation or contrast agents which should not be used on a regular basis. Ultrasound is non-invasive and does not expose the patient to radiation or contrast. I can use Visualize:Vascular on a regular basis with Ultrasound, giving me a detailed 3D understanding of the patient in every office visit."

"NEPVS is the largest vascular surgery practice in the Philadelphia, Pennsylvania area. Dr. Samhouri and his associates pride themselves on patient care and responsiveness in providing each patient with their own customized treatment plan. The practice diligently monitors each patient to determine the best choice in medical options and the improved care that can be achieved from close monitoring," commented Jeff Collins, President and CEO of the Medipattern Corporation. "Visualize:Vascular is being offered on a fee per-use model. Installations are expected to grow throughout next quarter as Visualize:Vascular continues to prove its clinical utility in daily practice. This growth should result in a steady increase in revenue for the company."

About The Medipattern Corporation:

Medipattern® is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Medipattern uses its Cadenza™ technology to process images, finding the salient region of interest and presenting them in 2D and 3D formats that enhance the reader's perception. For more information, please visit the Company's website: www.medipattern.com.

Medipattern® is a registered mark of The Medipattern Corporation. Visualize:Vascular™ is a trademark of the Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: The Medipattern Corporation Jeff Collins CEO (416) 744-0009 ext. 224 jcollins@medipattern.com www.medipattern.com Spinnaker Capital Markets Inc. Kevin O'Connor (416) 962-3300 ext. 226 ko@spinnakercmi.com